Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib plus bendamustine and rituximab for previously untreated chronic lymphocytic leukemia
2013-003313-17Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Idelalisib + bendamustine + rituximab with Placebo + bendamustine + rituximab (2 arms). Primary endpoint: Progression-free survival. Started Mar 2014; status: terminated.
02
Drugs
idelalisib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2013-003313-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003313-17.